Interventional Radiology


Stanford Interventional Radiology Department has a robust research enterprise. In particular, we focus on translational research, taking bench-top discoveries to the bedside. Our areas of focus are venous thromboembolism (deep venous thrombosis and pulmonary embolism), venous stenoses (May-Thurner Syndrome and chronic venous occlusions) and interventional oncology.

Deep Vein Thrombosis (DVT)/ Pulmonary Embolism (PE) Research

The aim of this research is to discover blood biomarkers and imaging characteristics of veins, which combined together, can predict which patients will develop a DVT or PE.

There are a number of active clinical trials in the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolisms (PE). Some of these studies are first in human studies aiming to provide better treatments for subjects with DVT/PE. For example, we have developed techniques to remove IVC filters that are imbedded into the wall of the inferior vena cava. For an overview and in-depth listing of our clinical trials, please visit our clinical trials page.

Venous Stenoses Research

Our group has pioneered the treatment of venous stenoses in patients with May-Thurner Syndrome or in patients that have blockages of their veins, typically from a previous deep venous thrombosis. We have already unraveled one of the main reasons women on birth control pills develop deep venous thrombosis, it was due to a normal variant in venous anatomy (May-Thurner Syndrome) that significantly increased their risk. We have published extensively other articles in this area and have a number of prospective and retrospective clinical trials on-going.

Interventional Oncology Research

We specialize in localize delivery of therapy directly to a tumor. Currently we use drugs (chemoembolization) or small radioactive beads (radioembolization). We are undertaking basic research to develop better treatments utilizing our current procedures. One of the current projects, VIPER, is aiming to develop a gene-therapy treatment that can be delivered using our current techniques. VIPER utilizes already FDA-approved agents. The research has been underway for over 3 years.

We are currently participating in a number of clinical trials looking at the treatment of liver cancer (hepatocellular carcinoma and metastatic cancer to the liver) and pancreatic cancer. For a full listing of our cancer clinical trials, please visit our clinical trials page.

Footer Links: